Healthcare provider profile · identity verified

Mozella Williams, MD

Family Practice · CONOWINGO, MD · NPI 1578608618

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	183	56
Lisinopril	Lisinopril	131	43
Levothyroxine Sodium	Levothyroxine Sodium	124	35
Losartan Potassium	Losartan Potassium	88	30
Amlodipine Besylate	Amlodipine Besylate	84	30
Metoprolol Succinate	Metoprolol Succinate	80	26
Metformin Hcl	Metformin Hcl	79	22
Omeprazole	Omeprazole	67	21
Albuterol Sulfate Hfa	Albuterol Sulfate	60	32
Furosemide	Furosemide	55	20
Hydrochlorothiazide	Hydrochlorothiazide	55	19
Montelukast Sodium	Montelukast Sodium	55	19
Rosuvastatin Calcium	Rosuvastatin Calcium	53	19
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	51	16
Oxycodone Hcl	Oxycodone Hcl	50	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	45	suppressed
Gabapentin	Gabapentin	41	12
Carvedilol	Carvedilol	40	13
Clopidogrel	Clopidogrel Bisulfate	36	suppressed
Prednisone	Prednisone	35	11
Escitalopram Oxalate	Escitalopram Oxalate	34	12
Fluticasone Propionate	Fluticasone Propionate	33	16
Glipizide Er	Glipizide	32	11
Trazodone Hcl	Trazodone Hcl	32	suppressed
Eliquis	Apixaban	29	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	28	suppressed
Simvastatin	Simvastatin	28	suppressed
Tramadol Hcl	Tramadol Hcl	28	suppressed
Famotidine	Famotidine	27	11
Pravastatin Sodium	Pravastatin Sodium	26	11
Duloxetine Hcl	Duloxetine Hcl	24	suppressed
Metformin Hcl Er	Metformin Hcl	24	14
Potassium Chloride	Potassium Chloride	24	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	23	suppressed
Ozempic	Semaglutide	23	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	23	suppressed
Farxiga	Dapagliflozin Propanediol	21	suppressed
Fenofibrate	Fenofibrate	20	suppressed
Januvia	Sitagliptin Phosphate	20	suppressed
Pregabalin	Pregabalin	20	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	20	16
Trulicity	Dulaglutide	20	suppressed
Varenicline Tartrate	Varenicline Tartrate	20	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	18	17
Azithromycin	Azithromycin	18	16
Chlorthalidone	Chlorthalidone	18	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	18	14
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	17	suppressed
Jardiance	Empagliflozin	17	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	16	suppressed
Celecoxib	Celecoxib	16	suppressed
Glimepiride	Glimepiride	16	suppressed
Spironolactone	Spironolactone	16	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	16	suppressed
Atenolol	Atenolol	15	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Fluconazole	Fluconazole	14	11
Fluoxetine Hcl	Fluoxetine Hcl	14	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Sertraline Hcl	Sertraline Hcl	14	suppressed
Bupropion Hcl	Bupropion Hcl	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	13	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	13	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	12	suppressed
Ezetimibe	Ezetimibe	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Methadone Hcl	Methadone Hcl	12	suppressed
Xarelto	Rivaroxaban	12	suppressed
Alendronate Sodium	Alendronate Sodium	11	suppressed
Azelastine Hcl	Azelastine Hcl	11	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error